Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2062914 | 1.00 | KEAP1 (0.56) | KEAP1NFE2L2MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL27821813 | 0.98 | KEAP1 (0.54) | KEAP1NFE2L2MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL27700604 | 0.98 | KEAP1 (0.54) | KEAP1NFE2L2MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL4889259 | 0.81 | KEAP1 (0.51) | KEAP1NFE2L2MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL9193099 | 0.80 | MAPT (0.52) | KEAP1NFE2L2MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL198459 | 0.80 | MAPT (0.52) | KEAP1NFE2L2MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL12531908 | 0.80 | MAPT (0.52) | KEAP1NFE2L2MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL6589615 | 0.78 | KEAP1 (0.47) | KEAP1NFE2L2MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL609929 | 0.73 | MEN1 (0.43) | KEAP1NFE2L2MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL4608035 | 0.72 | KEAP1 (0.58) | KEAP1NFE2L2MAPTL3MBTL1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101466349-A | Piperidinium compounds and cosmetic compositions containing them | BEIERSDORF AG (DE) | 2009-06-24 | — | — | CN | claimed |
| EP-3432855-A1 | ANTIPERSPIRANT STICK IN THE FORM OF A O/W EMULSION | Beiersdorf AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| CN-102947309-B | 7-aza-bicyclo [2.2.1] heptane derivatives, process for their preparation, and their pharmaceutical use | THERON PHARMACEUTICALS, INC. (US) | 2016-02-10 | — | — | CN | disclosed |
| US-9216971-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-22 | — | — | US | disclosed |
| CN-104744480-A | 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof | THERON PHARMACEUTICALS INC | 2015-07-01 | — | — | CN | disclosed |
| CN-104288143-A | Glycopyrrolate and neosigmine methylsuIfate combined injection and preparation method thereof | ANHUI YI XIN MING PHARMACEUTICAL CO LTD | 2015-01-21 | — | — | CN | disclosed |
| US-20140329857-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8628759-B2 | Soft anticholinergic esters | BODOR LABORATORIES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8492407-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| CN-102947309-A | 7-aza-bicyclo [2.2.1] heptane derivatives, process for their preparation, and their pharmaceutical use | THERON PHARMACEUTICALS INC | 2013-02-27 | — | — | CN | disclosed |
| US-8202891-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8147809-B2 | Soft anticholinergic esters | BODOR LABORATORIES, INC. | 2012-04-03 | — | — | US | disclosed |
| US-20090263341-A1 | SOFT ANTICHOLINERGIC ESTERS | BODOR LABORATORIES, INC. | 2009-10-22 | — | — | US | disclosed |
| US-7576210-B2 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives; 6 beta ,7 beta -epoxy-3 beta -hydroxy-8-ethoxycarbonylmethyl-8-methyl-1 alpha H,5 alpha H-tropanium bromide, di-2-thienylglycolate | BODOR LABORATORIES, INC. | 2009-08-18 | — | — | US | disclosed |
| US-20090075954-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives; 6 beta ,7 beta -epoxy-3 beta -hydroxy-8-ethoxycarbonylmethyl-8-methyl-1 alpha H,5 alpha H-tropanium bromide, di-2-thienylglycolate | BODOR LABORATORIES, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20080269190-A1 | Chronic obstructive pulmonary disease; asthma | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |
| EP-1948596-A2 | SOFT ANTICHOLINERGIC ESTERS | Bodor, Nicholas S. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-7399861-B2 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2008-07-15 | — | — | US | disclosed |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2007-05-31 | — | — | US | disclosed |
| WO-2007058971-A2 | SOFT ANTICHOLINERGIC ESTERS | BODOR NICHOLAS S (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263341-A1 | SOFT ANTICHOLINERGIC ESTERS | CHRM2, CHRM1, CHRM3 | KEAP1 2565/4885NFE2L2 3626/4885MAPT 2149/4885 |
| US-20080269190-A1 | Chronic obstructive pulmonary disease; asthma | CHRM2, CHRM5, CHRM3 | KEAP1 2365/4885NFE2L2 4302/4885MAPT 3972/4885 |
| US-20090075954-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives; 6 beta ,7 beta -epoxy-3 beta -hydroxy-8-ethoxycarbonylmethyl-8-methyl-1 alpha H,5 alpha H-tropanium bromide, di-2-thienylglycolate | CHRNE, CHRM1, ADRB1 | KEAP1 2309/4885NFE2L2 2306/4885MAPT 3768/4885 |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | CHRM2, ADRB1, ADRB2 | KEAP1 1890/4885NFE2L2 2183/4885MAPT 3923/4885 |
| US-20140329857-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | KEAP1 2835/4885NFE2L2 4682/4885MAPT 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.